Dr Dionysis Papadatos-Pastos
Dr. Papadatos-Pastos is a distinguished thoracic oncologist specialising in lung cancer, mesothelioma, thymoma, and thymic cancer. With an extensive publication record in leading medical journals, he is a sought-after speaker and contributor to national and international conferences. Dr. Papadatos-Pastos adopts a multidisciplinary approach to deliver personalised and comprehensive care for his patients.
Bio
Dr Dionysis Papadatos-Pastos is a leading thoracic oncologist in London with over 20 years of experience in the diagnosis and treatment of lung cancer, mesothelioma, thymoma, and thymic cancer. He is recognized for combining cutting-edge cancer treatments with compassionate, patient-centered care.
Dr Papadatos-Pastos graduated in Medicine with distinction from the University of Athens, followed by a PhD in Medical Oncology (biomarkers, 2012, First Class honors). He trained in oncology at top UK cancer centers and completed a fellowship at the Royal Marsden’s Phase I Clinical Trials Unit, focusing on the development of targeted therapies and immunotherapy combinations for non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and mesothelioma. He also holds a Diploma in Medical Oncology from the Institute of Cancer Research, University of London.
He is the Lead for Lung Cancer at the CRUK UCL Clinical Trials Centre and Co-Chair of The London Clinic Lung Cancer MDT, where he develops highly personalized treatment plans through a multidisciplinary team approach.
A dedicated researcher, Dr Papadatos-Pastos has served as principal investigator on numerous academic and industry clinical trials and received the ASCO Merit Award (2010). His research, published in leading international journals, focuses on precision oncology, immunotherapy, and targeted treatment strategies. He is regularly invited to present at national and international conferences on novel therapies for lung cancer and mesothelioma.
Outside of his clinical and research commitments, Dr Papadatos-Pastos is actively involved in mentoring junior doctors, enjoys swimming, and values spending quality time with his family.
Areas of expertise
- Non-small cell lung cancer
- Small cell lung cancer
- Mesothelioma
- Thymoma
- Thymic cancer
More information
146 Harley Street
London, W1G 7JL
- ASCO Merit Award 2010
- Qualified 2002
- National and Kapodistrian University of Athens 1995-2002
- Consultant in Medical Oncology
University College London Hospitals - Consultant in Medical Oncology
The Princess Alexandra Hospital
Articles
Article: Living with Purpose: Lynda’s Journey with Cancer
Research
As the Principal Investigator of the HyPeR clinical trial (NIHR UCLH Clinical Research Facility), Dr Papadatos-Pastos leads efforts to understand and overcome resistance to immunotherapy in lung cancer. The trial is investigating the mechanisms behind immunotherapy resistance and explores whether adding a novel drug to immunotherapy can reverse this resistance and improve outcomes. Early results have been encouraging, demonstrating potential to enhance treatment response. These findings have been published in a respected oncology journal, highlighting the trial’s clinical significance. Dr Papadatos-Pastos continues to oversee patient enrolment, treatment protocols, and data analysis, aiming to refine and expand immunotherapy options for lung cancer patients.
- RCP
- MDU
Dr Papadatos-Pastos has been featured in print publications such as The Guardian, The Evening Standard and Cosmopolitan UK.
